Buyer is aware...
For 2$ offer per share buyers is paying 1$ or 30 millions (after tax losses and cash consolidation).
Basically, 30 millions for 3 compounds in late stage. 3 niche market application and orphan drug status designation.
For 1$ offer per share is getting the company for free (after tax losses and cash consolidation).
Basically, putting their hands on 3 compounds....
Trigger will be interim results. Trigger for partnership or buyout...
It is impossible not to take a swipe at buying TLN, there is just too much value and so little comprehension from the current shareholder base....
TLN need to find 100-120 millions to commercialized all 3 compounds.
From, 0,20$ to 9,40$....
Impressive results could move market cap to 300 millions, and from there anything can happen.
Giving a market of 300 millions for TLN, gives us an average price of 9,40$ per share.
Management is certainly aiming for something in the 150 millions. Around and above 4$ per shares...
Everything looks great for this company...